J. B. Chemicals & Pharmaceuticals Limited (JBCPL), one of the fastest growing pharmaceutical companies in India, announced its financial results for the second quarter ended 30th September, 2021.
Quarterly Financial Performance – Q2 FY22 vs Q2 FY21
For the second quarter ended 30th September 2021, the Company recorded revenue of INR 593 crores as compared to INR 444 crores, registering a growth of 34% over the corresponding quarter ended 30th September, 2020. Operating EBITDA* (Earnings Before Interest Depreciation and Taxes) increased by 27% to INR 140 crores as compared to INR 110 crores. Adjusted EBITDA** increased by 40 % to INR 154 crores. Profit after Tax stood at INR 98 crores as compared to INR 74 crores registering growth of 32%.
Commenting on financial results, Nikhil Chopra, CEO and Wholetime Director, JBCPL said, “Our strong operational performance has led to market beating growth in India and steady performance in international business despite pandemic related issues and supply chain uncertainties.” He further added “During the past one year, several initiatives including the re- aligned Go-To-Market model, diversification into complimentary therapies and new launches have helped us sustain our growth momentum in India leading to market share gains and rank improvement. While international business is confronted with external market challenges, our key markets like South Africa and the US have done well and Russia is showing signs of steady revival. We are working aggressively on expanding our offerings in the international market by reorienting our R&D and aggressively pursuing business development opportunities. Going forward, our priority will be to further optimise our cost structure and continue to build on the revenue momentum in line with our strategic priorities.”